.jpg){kind=link}
- Published
- Updated
- Sources checked
A clinical hold response should explain how each FDA concern has been addressed and what changed to protect participants. A traceable response package helps the sponsor avoid confusing a completed submission with permission to resume a held investigation.
Read the scope of the hold
21 CFR 312.42 defines a clinical hold as an FDA order delaying a proposed investigation or suspending an ongoing one. Establish which protocols and activities are covered from the actual communication; do not assume that every investigation under the IND has the same status.
Prepare a concern-response matrix
Link each FDA concern to a response, rationale, supporting evidence and changed document. Show which issues remain open in a partial response. Communicate arrangements for current participants’ treatment and follow-up clearly between investigators and the sponsor’s regulatory and medical teams.
Review the response package
Where new data or protocol changes are generated, match approved report versions to the package. A reviewer should be able to locate support for each response claim. Track the sponsor’s assessment that an issue is resolved separately from the subsequent FDA decision.
- Map every hold concern to a response entry.
- Verify revised protocol and supporting report versions.
- Communicate the FDA restart decision to affected sites.
Preserve restart conditions
Submitting a response does not mean the study can restart. Do not resume held activities until FDA permits resumption. Review site communication, updated consent, training and suitable materials when preparing to restart, and retain evidence of the scope of the permission received.
Frequently asked questions
- Does delivery of the response lift the hold?
- No. Resumption depends on FDA communication and the scope of the hold.
- Can a response contain only partial information?
- Keep unresolved concerns explicit and distinguish partial information from a claim that all issues are addressed.